STOCK TITAN

Genetic Technologies Ltd. - GENE STOCK NEWS

Welcome to our dedicated page for Genetic Technologies Ltd. news (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies Ltd. stock.

Genetic Technologies Ltd. (ASX: GTG, NASDAQ: GENE) is a pioneering molecular diagnostics company based in Australia, specializing in genetic testing and reproductive services. The company leverages an extensive array of international patents and allied research activities to explore the profound impact of DNA on health. Its operations span across the Asia Pacific region, offering specialized genetic tests that convert advanced health knowledge into practical applications for humans, animals, and plants.

One of the company's flagship products is BREVAGenplus, a clinically validated risk assessment test that helps in predicting the likelihood of non-hereditary breast cancer. This test has been a game changer in women's health, providing crucial insights that aid physicians in proactive health management. BREVAGenplus is primarily marketed to healthcare professionals, including breast healthcare and imaging centers, obstetricians/gynecologists (OBGYNs), and breast cancer risk assessment specialists.

Genetic Technologies Ltd. offers a broad spectrum of genetic testing services, encompassing medical, animal, forensic, and plant testing. The company's revenue is chiefly derived from markets in Australia and the United States. The organization operates through two primary segments: EasyDNA and GeneType/Corporate.

Recent developments underline the company’s ongoing commitment to innovation and expansion. For example, the company has recently reported the clinical adoption of its groundbreaking geneType Risk Assessment Tests across 12 states in the United States and at a national level in Australia. These tests are designed to provide a comprehensive risk assessment for various diseases, thereby enabling personalized healthcare.

Dr. Carolyn Young, a board-certified Obstetrician and Gynecologist based in Rockville, Maryland, has emphasized the significance of such tests. According to her, misconceptions about breast cancer risks—such as the belief that absence of family history equates to low risk—can be clarified through the use of geneType tests, which identify both hereditary and non-hereditary risks.

The company continues to make strides, as highlighted in their recent announcements. Genetic Technologies Ltd. aims to expand its market reach by launching new comprehensive tests and entering new global markets. These initiatives are part of the company’s strategic efforts to cement its position as a global leader in genomics-based tests in health, wellness, and serious disease.

For further information or inquiries, you can reach out to Simon Morriss, Chief Executive Officer, at investors@genetype.com.

Rhea-AI Summary
Genetic Technologies reports annual results, with revenues of A$8.686 million, a +28% increase compared to 2022. Encouraging growth in geneType testing volumes. Development of Comprehensive Breast & Ovarian Cancer Risk Test. Strategic alliance with QIAGEN. Aim to attain profitability in the next 18 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
News
Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) announced significant growth in its quarterly business update for Q3 FY23, reflecting ongoing momentum in its genomics-based testing market.

Key highlights include:

  • Receipt of A$4.22 million in the March quarter, with A$2.23 million from customers, a 13% increase year-on-year.
  • Year-to-date customer receipts of A$6.7 million, up 45% from the prior period.
  • Expansion of the geneType multi-test panel to cover nine diseases.
  • Formation of a strategic alliance with QIAGEN to enhance market position.
  • Introduction of the world’s first Comprehensive Breast & Ovarian Cancer Risk Test.

GTG remains focused on achieving breakeven cash flow by leveraging its multi-brand strategy and partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
-
Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) announced a significant advancement in prostate cancer risk assessment with the publication of a study validating its geneType Prostate Cancer Risk Assessment Test. This test identifies 23% more men at high risk of prostate cancer compared to family history alone, enhancing the effectiveness of PSA screening methods. The research involved nearly 200,000 men from the UK Biobank and marks the fifth publication in the past six months on their geneType suite of tests. This development underscores GTG's commitment to improving health outcomes and reducing unnecessary medical interventions by providing a more targeted screening approach. The test is now commercially available, reflecting the ongoing scientific development in genomics-based health testing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
-
Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) has announced the US launch of three new disease assessments, expanding its geneType Multi-Test to include melanoma, pancreatic cancer, and atrial fibrillation. This addition raises the total number of risk assessments to nine from a single saliva sample. The updated test is now available for all ethnicities and provides risk stratification for various serious diseases, enhancing early detection and patient outcomes. According to estimates, melanoma and pancreatic cancer will see approximately 97,610 and 64,050 new cases respectively in 2023, emphasizing the importance of this testing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
none
Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) announced the publication of a new research paper in Cancer Prevention Research, reinforcing the efficacy of its geneType Breast Cancer Risk Assessment Test. This study, utilizing over 200,000 women from the UK Biobank, highlights geneType's superior performance over traditional models like BCRAT over a five-year period. Notably, women classified at ≥3% risk by geneType exhibited a 1.829 times higher incidence of breast cancer. This marks the second peer-reviewed publication in a month, supporting geneType’s role as a crucial risk stratification tool for the general population, and reflects the company’s commitment to clinical validation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
none

FAQ

What is the current stock price of Genetic Technologies Ltd. (GENE)?

The current stock price of Genetic Technologies Ltd. (GENE) is $0.765 as of October 22, 2024.

What is the market cap of Genetic Technologies Ltd. (GENE)?

The market cap of Genetic Technologies Ltd. (GENE) is approximately 3.7M.

What is Genetic Technologies Ltd. known for?

Genetic Technologies Ltd. is known for its pioneering work in molecular diagnostics, offering predictive genetic tests and assessment tools, including the clinically validated BREVAGenplus for non-hereditary breast cancer.

What are the main services offered by Genetic Technologies Ltd.?

The company provides a range of genetic testing services such as medical testing, animal testing, forensic testing, and plant testing.

Where does Genetic Technologies Ltd. generate most of its revenue?

The majority of the company's revenue comes from Australia and the United States.

What is BREVAGenplus?

BREVAGenplus is a clinically validated risk assessment test designed to predict the risk of non-hereditary breast cancer.

Who primarily uses BREVAGenplus?

BREVAGenplus is marketed to healthcare professionals, including those in breast healthcare and imaging centers, obstetricians/gynecologists (OBGYNs), and breast cancer risk assessment specialists.

What are the company's main operating segments?

Genetic Technologies Ltd. operates through two main segments: EasyDNA and GeneType/Corporate.

What recent milestones has Genetic Technologies Ltd. achieved?

The company has recently reported clinical adoption of its geneType Risk Assessment Tests across 12 states in the United States and nationally in Australia.

Who can I contact for more information about Genetic Technologies Ltd.?

You can reach out to Simon Morriss, Chief Executive Officer, at investors@genetype.com for more information.

What is the focus of Genetic Technologies Ltd.'s research?

The company focuses on uncovering the impact of DNA on health through extensive research and an array of international patents.

How does Genetic Technologies Ltd. contribute to women's health?

Genetic Technologies Ltd. contributes to women's health through its predictive testing and assessment tools, particularly the BREVAGenplus test, which helps manage the risk of non-hereditary breast cancer.

Genetic Technologies Ltd.

Nasdaq:GENE

GENE Rankings

GENE Stock Data

3.71M
4.85M
1.87%
0.53%
Diagnostics & Research
Healthcare
Link
United States of America
Prahran